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Edited by Lukas HuberAbstract Cannabinoids (CBs) are implicated in the control of
cell survival in diﬀerent types of tumors, but little is known about
the role of CB system in pancreatic cancer. Herein, we investi-
gated the in vitro antitumor activity of CBs and the potential role
of their receptors in human pancreatic cancer cells MIA PaCa-2.
Characterization tools used for this study included growth inhibi-
tion/cell viability analyses, caspase 3/7 induction, DNA fragmen-
tation, microarray analysis and combination index-isobologram
method. Our results demonstrate that CBs produce a signiﬁcant
cytotoxic eﬀect via a receptor-independent mechanism. The CB1
antagonist N-(piperidin-1-1yl)-5-(4-iodophenyl)-1-(2,4-dichlor-
ophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) was
the most active compound with an IC50 of 8.6 ± 1.3 lM after
72 h. AM251 induces apoptosis, causes transcriptional changes
of genes in janus kinase/signal transducers and activators of
transcription signaling network and synergistically interacts with
the pyrimidine analogue, 5-ﬂuorouracil. These ﬁndings exclude
the involvement of CB receptors in the regulation of MIA
PaCa-2 cell growth and put AM251 forward as a candidate
for the development of novel compounds worthy to be tested in
this type of neoplasia.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Cannabinoids; Pancreatic cancer; Apoptosis;
Microarray; Synergism1. Introduction
Several ﬁndings support the role of cannabinoids (CBs) and
their derivatives in cell growth inhibition and apoptosis induc-
tion in tumor cells [1,2]. The plethora of experimental observa-
tions regarding the mechanism involved in the antiproliferative
action of cannabinoids is in line with their pleiotropic nature.Abbreviations: CBs, cannabinoids; JAK-STAT, janus kinase/signal
transducers and activators of transcription; ACEA, arachidonyl-2 0-
chloroethylamide; JWH-015, (2-methyl-1-propyl-1H-indol-3-yl)-1-na-
phthalenylmethanone; AM251, (N-(piperidin-1-1yl)-5-(4-iodophenyl)-
1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide); AM630,
(4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carboxa-
mido] benzoic acid); 5-FU, 5-ﬂuorouracil; IC50, 50% inhibitory
concentration; MAPK, mitogen-activated protein kinase
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doi:10.1016/j.febslet.2006.02.024From a molecular viewpoint, receptor-ligand binding appears
to play a key role in CB-mediated cytotoxic eﬀects, as demon-
strated for WIN-55,212-2 (mixed CB1/CB2 receptors agonist)
on human prostate cells LNCaP [3]. On the contrary, several
observations on cancer cells which express both CB1 and
CB2 receptors underline the irrelevance of CB receptor status
in determining drug response [4–6]. For instance, the ability
of cannabidiol to impair the migration of U87 glioma cells
was not antagonized by the selective receptor antagonists
SR141716 (CB1) and SR144528 (CB2) [4], while d
9-tetrahydro-
cannabinol (THC)-mediated apoptosis in leukemic cell lines [5]
and in human prostate PC-3 cells [6] was independent of the
CB receptors. Moreover, immunohistochemical and functional
analyses in mouse models of glioma [7] and skin carcinoma [8]
have shown that CBs may exert their antitumor eﬀects by
blocking the angiogenic process.
Despite the above mentioned observations, we need to be
cautious when envisaging the potential clinical use of new anti-
cancer therapies. As a matter of fact, nanomolar concentra-
tions of d9-tetrahydrocannabinol lead to epidermal growth
factor receptor-mediated increase in glioblastoma and lung
carcinoma cell proliferation [9], suggesting that biological re-
sponses to CBs critically depend on drug concentration and
type of cell examined.
The aim of the present study was to investigate the eﬀect of
CBs on the human pancreatic cancer cells MIA PaCa-2 since,
to date, no data have been produced on the putative role of CB
system in this speciﬁc cancer cell type.2. Materials and methods
2.1. Chemicals
The following CBs were used: WIN-55,212-2, CB1/CB2 receptor
agonist; ACEA, CB1 receptor-selective agonist; JWH-015, CB2 recep-
tor-selective agonist; AM251 and SR141716A, CB1 receptor-selective
antagonists; AM630, CB2 receptor-selective antagonist (Tocris, North-
point, UK). 5-ﬂuorouracil (5-FU; Sigma–Aldrich, St. Louis, MO,
USA) was used as reference drug. The reversible inhibitor of caspase
3/7, 5-[(S)-(+)-2-(methoxymethyl)pyrrolidino]sulfonylisatin, was ob-
tained from Calbiochem (La Jolla, CA, USA). Compounds were dis-
solved in dimethyl sulfoxide (DMSO) and further diluted in sterile
culture medium immediately before their use.
2.2. Cell culture
The human pancreatic cancer cell line MIA PaCa-2 was obtained
from the American Type Culture Collection (ATCC, Rockville, MD)
and cultured in DMEM medium supplemented with L-glutamineblished by Elsevier B.V. All rights reserved.
1734 S. Fogli et al. / FEBS Letters 580 (2006) 1733–1739(2 mM), 10% fetal bovine serum, 2.5% horse serum, 50 IU/ml penicillin
and 50 lg/ml streptomycin (Sigma–Aldrich, Milano, Italy) at 37 C in
an atmosphere of 5% CO2.
2.3. Growth inhibition assay
Cells (8 · 103/well) were seeded in 24-well plate and incubated for
24 h at 37 C to adhere completely to plastic and start growing. After
that, the medium was changed and cells were treated with CBs at 0.01–
100 lM for 24, 48 and 72 h. Cells were harvested and counted by
haemocytometer, and the growth of treated cells was expressed as a
percentage of the untreated control cells. The concentration of drugs
that decreased cell count by 50% (IC50) was calculated by nonlinear
least-squares curve ﬁtting of experimental data (GraphPad Software,
San Diego, CA, USA).
2.4. Cell viability assay
Cell viability was measured using a method based on the cleavage of
the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
disulfonate (WST-1) to formazan by mitochondrial dehydrogenase
activity (Cell proliferation reagent WST-1; Roche, Mannheim, Ger-
many). Cells (2 · 103/well) were seeded in 96-well plate in medium con-
taining 20% FBS and 2.5% HS, 1% FBS and 0.25% HS or serum-free
medium and received CBs from 0.14 to 312 nM, depending on their Ki
for CB receptors, and at 10 lM for 24, 48 and 72 h. Following drug
exposure, WST-1 was added and the absorbance was measured at
450 nm using a microplate reader.
2.5. RT-PCR characterization of CBs receptors
RNA from Mia PaCa-2 cells was extracted by using the SV total
RNA isolation system (Promega, Madison, WI, USA), reverse-tran-
scribed by the OmniScript RT kit and PCR was performed by the Hot-
StartTaqMaster Mix kit (Qiagen, Valencia, CA, USA). cDNA samples
were ampliﬁed for 35 cycles: 1 min at 95 C; 1 min at 56.8 C (CB1),
58 C (CB2) or 55 C (GAPDH); 1 min at 72 C, plus elongation step
at 72 C for 10 min. Primers used were: 5 0-CCACTCCCGCAGC-
3 0(F) and 5 0-ATGAGGCAAAACGCCACCAC-30(R) for CB1;
5 0-CGCCGGAAGCCCTCATAC-3 0(F) and 5 0-CCTCATTCGGGC-
CATTCTTG-3 0(R) for CB2; 5 0-GTGAAGGTCGGTGTCAACG-
3 0(F) and 5 0-GGTGAAGACGCCAGTAGACTC-3 0(R) for GAPDH
and the expected ampliﬁcation products were 293, 522 and 299 bp long,
respectively. CB1 and GAPDH primers were designed by Oligo-Primer
Analysis Software 4.0 (http://www.oligo.net/) whereas CB2 primers se-
quences were retrieved from McKallip et al. [10]. Human lymphocytes-
derived genomic DNA from a healthy volunteer was used as positive
control for testing CB1 and CB2 primers eﬃciency.
2.6. Caspase activity assay
Enzyme activity was assessed by the Apo-ONE Homogeneous
Caspase-3/7 assay substrate (Promega, Madison, WI, USA). Cells were
seeded at 2–7 · 103/wells and treated with CBs or 5-FU at 10 lM for
24, 48 and 72 h. Subsequently, the Caspase-3/7 assay substrate was
added and the ﬂuorescence was measured by spectroﬂuorimeter at
excitation and emission wavelengths of 485 and 530 nm, respectively.
Values were expressed as ratio between ﬂuorescent signals generated
in cells treated with CBs or 5-FU and those produced in untreated cells
(vehicle alone).
2.7. DNA fragmentation assay
Cells were treated at AM251 10, 50 and 100 lM for 24, 48 and 72 h.
Cells harvested by trypsinization were combined with detached cells
and apoptosis was assessed by the Cell Death Detection ELISA kit
(Roche, Mannheim, Germany) based on the recognition of released
nucleosomes after DNA internucleosomal fragmentation by a mouse
monoclonal antibody directed against DNA and histones.2.8. Microarray assay
Total RNA was isolated from AM251 (10 lM for 24 h)-treated and
untreated (vehicle alone) MIA PaCa-2 cells by using the RNeasy
puriﬁcation kit (Qiagen, Valencia, CA, USA). DNaseI treated
RNA was ampliﬁed and dye-labeled with Cy3 or Cy5 by using the
Amino Allyl MessageAmp II aRNA Ampliﬁcation Kit (Ambion,
Austin, TX, USA). Competitive hybridizations on high-density oligo-
nucleotide microarray slides, containing 21329 sequences from theOperon 2.0 oligoset (Microcribi, Padua, Italy), were automatically
performed by Lucidea Automatic Slide Processor (GE Healthcare
Technologies, UK). We ran three independent experiments, each time
in ‘‘dye swap’’ to eliminate potential bias due to diﬀerences in dye
labelling eﬃciency, for a total of six hybridizations.
2.9. Microarray data acquisition and analysis
Hybridized slides were scanned with Genepix 4000B scanner using
GenepixPro 4.0 software (Molecular Devices, Sunnyvale, CA, USA).
Resulting ﬁles were analyzed within the R environment by making use
of the ‘‘Limma’’ package (http://www.bioconductor.org). The loaded
data were ﬁltered by adding additional ‘‘Bad’’ ﬂags to those spots which
had not an acceptable signal to noise ratio (SNR); the ‘‘Bad’’ spots were
discarded from the successive analysis. The print-tip normalization was
applied to the data and the Bayesian statistics B were calculated for each
gene with the ‘‘Limma’’ package (http://www.bioconductor.org).
The list of diﬀerentially regulated genes was analyzed by Onto-Ex-
press and Pathway-Express tools (http://vortex.cs.wayne.edu/pro-
jects.htm) to ﬁnd signiﬁcantly impacted biological processes.
2.10. Real-Time PCR validation of microarray data
Total RNA was reverse transcribed by SuperScript III kit (Invitro-
gen, Carlsbad, CA, USA). Primer sequences were designed using Bea-
con Designer 4.0 software (Biorad, Hercules, CA, USA) and are
available upon request. PCR ampliﬁcations were performed with Plat-
inum Sybr Green QPCR Supermix (Invitrogen, Carlsbad, CA, USA)
by using an iCycler iQ Real-Time PCR detection system (Biorad, Her-
cules, CA, USA). For each sample, expression of the human cyto-
chrome c-1 (CYC1) gene was used to normalize the amount of the
investigated transcript. Relative expression levels were calculated with
respect to the expression level in the untreated sample and were ex-
pressed as fold increase or decrease.
2.11. Quantitation of the synergism between AM251 and 5-FU
Cells were seeded at 8 · 103/well and treated with 5-FU in the range
of 0.5–75 lM alone or in combination with AM251 at 1, 10 and 50 lM
for 72 h. The combination index-isobologram method [11] was applied
to analyze data from the in vitro drug-combination study. Brieﬂy, syn-
ergism or antagonism for AM251 plus 5-FU was calculated on the ba-
sis of the multiple drug-eﬀect equation, and quantiﬁed by the
combination index (CI), where CI < 1, CI = 1, and CI > 1 indicate syn-
ergism, additive eﬀect, and antagonism, respectively. Based on the clas-
sic isobologram for mutually exclusive eﬀects, CI values were
calculated as follows: CI = [(D)1/(Dx)1] + [(D)2/(Dx)2], where (D)1 and
(D)2 are the concentrations of AM251 and 5-FU in combination that
induce a x% of cell growth inhibition (isoeﬀective as compared with the
single drugs alone) while, (Dx)1 and (Dx)2 are the concentrations for
x% inhibition by AM251 and 5-FU, respectively. Dx values were ob-
tained from the following equation: (Dx) = Dm[fa/(1  fa)]1/m, where
Dm is the median-eﬀect dose (ED50) of the single drug, fa is the frac-
tional inhibition, (1  fa) is the fraction unaﬀected, and m is the coef-
ﬁcient signifying the shape of the dose–eﬀect curves.
The dose-reduction index (DRI) deﬁnes the extent (fold change) of
concentration reductions that are possible in a combination schedule
for a given degree of eﬀect as compared with the concentration of each
drug alone as follows: (DRI)1 = (Dx)1/(D)1 and (DRI)2 = (Dx)2/(D)2.
The DRI values for actual combination data points were calculated
from the results obtained from CI equation.
2.12. Statistical analysis
Data were presented as mean values ± standard error (S.E.). Statisti-
cal comparisons among groups were performed by Student’s t-test or
one-wayanalysis of variance (ANOVA) followedby theNewman–Keuls
test for multiple comparison. Signiﬁcance was assumed at P < 0.05.3. Results
3.1. In vitro antitumor activity of CBs and role of CB receptors
Irrespective of their pharmacological proﬁles on CBs recep-
tors, CBs produced a concentration- and time-dependent MIA
PaCa-2 cell growth inhibition (Table 1). Accordingly, CBs at
Table 1
Cannabinoid-mediated cell growth inhibition in the range of 0.01–100 lM after 24, 48 and 72 h
Compounds IC50 (lM)
24 h 48 h 72 h
ACEA 48.2 ± 3.4 23.9 ± 8.7 16.9 ± 1.7
AM251 44.4 ± 3.8 18.7 ± 2.9 8.6 ± 1.3*
JWH-015 42.4 ± 2.4 20.0 ± 2.0 17.0 ± 1.4
AM630 64.6 ± 1.9 63.5 ± 8.7 19.2 ± 1.7
Experiments were performed in triplicate and values are expressed as means ± S.E.; *P < 0.05, as compared to the IC50 of the other cannabinoids
after 72 h.
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on these compounds.
Fig. 1C shows the RT-PCR product corresponding to CB1
receptor, whose identity was conﬁrmed by DNA sequencing.
The mRNA of CB2 receptor was not detected on MIA
PaCa-2 cells, although the positive control for CB2 receptor
on human lymphocytes-derived genomic DNA clearly demon-
strated the quality of CB2 primers. Furthermore, at concentra-
tions 0.1–10-fold their Ki for CB receptors, both the selective
CB1 receptor agonist and antagonist, ACEA and AM251,
did not signiﬁcantly aﬀect cell viability both in normal-serum
and serum-free medium (Fig. 1D). Finally, the antiprolifera-
tive eﬀect of ACEA was not prevented by AM251 at the
non-cytotoxic concentration of 1 lM (Fig. 1E).
3.2. Eﬀect of CBs on apoptosis
At variance with the other CBs as well as the reference drug,
5-FU, the magnitude of AM251 eﬀect on caspase 3/7 was re-
lated to the time of exposure to the drug. Particularly,
AM251 at 10 lM for 24 h induced enzyme activities
(1.78 ± 0.22 fold stimulation vs. control; P < 0.01) which were
further enhanced at 3.01 ± 0.34 and 8.18 ± 0.34 fold stimula-
tion (P < 0.001) after 48 and 72 h, respectively (Fig. 2A).
Fig. 2B demonstrates that 5-[(S)-(+)-2-(methoxymethyl)pyrr-
olidino]sulfonylisatin, a reversible inhibitor of caspase 3/7, par-
tially reverses the toxicity of AM251. Finally, AM251 at 10, 50
and 100 lM for 24–72 h, signiﬁcantly increased the production
of cytosolic histone-associated DNA fragments in a concentra-
tion- and time-dependent manner (Fig. 2C).
3.3. Signaling pathways involved in AM251 antitumor activity
Thirty-nine genes were downregulated while 46 genes were
upregulated after AM251 at 10 lM for 24 h. Onto-Express
automatically translated such a list of diﬀerentially regulated
genes into functional proﬁles with the result of 63.5% of genes
assigned to ‘‘cellular process’’ category which, in turn, includes
genes involved in cell death, cell cycle and regulation of cell
proliferation. Furthermore, pathway-express analysis indi-
cated that AM251 treatment induced a modulation of genes
of highly-regulated signaling networks critical for cell fate
including janus kinase/signal transducers and activators of
transcription (JAK-STAT) and mitogen-activated protein ki-
nase (MAPK) signaling pathways and cell cycle, as well.24 48 72
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Fig. 2. (A) Induction of caspase 3/7 activities by CBs at 10 lM for 24, 48 a
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fragmentation of internucleosomal DNA after AM251 at 10, 50 and 100 lMFig. 3A shows a multilevel molecular targeting which may rep-
resent a conceivable hypothetical framework of the AM251
mechanism of action.
The complete list of the diﬀerentially expressed genes is
available in supplementary material. Further information can
be retrieved from the ArrayExpress database at the European
Bioinformatics Institute (EBI) (http://www.ebi.ac.uk/arrayex-
press/) by using the following accession numbers: E-MAXD-
9 for the experiment and A-MAXD-4 for the array. Micro-
array results were validated by quantitative real-time PCR
which conﬁrmed the AM251-induced changes of a representa-
tive cohort of genes (Fig. 3B shows some examples of genes
validated by real-time PCR).
3.4. Synergistic interaction between AM251 and 5-FU
Fig. 4A shows that, in the presence of AM251 at the non-
cytotoxic concentration of 1 lM (Fig. 4B), the dose–response
curve of 5-FU shifted to the left with the result of a signiﬁcant
reduction (P < 0.01) of the IC50 value from 6.0 ± 0.2 to
3.7 ± 0.2 lM (5-FU alone and in combination schedule,
respectively). Sample calculation for the combination index
(CI) values of AM251 at 1 lM plus 5-FU from 0.5 to 5 lM,
demonstrated synergism (CI < 1) and a favorable dose-reduc-
tion index (DRI > 1) for both the drugs at eﬀect levels from
18.3 ± 1.8 to 58.2 ± 1.8% inhibition (Table 2; Fig. 4A). The
AM251 combination with 5-FU at 10 and 25 lM produced
an additive eﬀect while, when AM251/5-FU was given at 10/
0.5 and 50/0.5 ratio, antagonism was observed on MIA
PaCa-2 cells (Table 2). AM251 at 10 and 50 lM dose-depen-
dently increased growth inhibition by 5-FU (Fig. 4A); in these
conditions, antagonism, in the presence of favorable DRI val-
ues, was also observed (Table 2).4. Discussion
The present study demonstrates in vitro anticancer activity
of CB derivatives on the poorly diﬀerentiated pancreatic can-
cer cell line MIA PaCa-2. Our data indicate that such an eﬀect
may be mediated via a receptor-independent mechanism and
this notion is supported by the following pieces of evidence:
(i) both selective CB1 and CB2 receptors agonists and antago-
nists were cytotoxic; (ii) the absence of CB2 receptors clearly24 48 72
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(iii) at nanomolar concentrations, CB1 receptor agonist and
antagonist did not signiﬁcantly change cells viability in ser-
um-free medium, a condition in which non-speciﬁc interactions
with serum components were avoided; and (iv) at micromolar
doses, CB1 receptor did not account for the ACEA-mediated
cell death.Taking into account their lipophilic nature, it is conceivable
that CBs may exert cytotoxic eﬀects by crossing cell membrane
and directly or indirectly disrupting cellular network with the
result of a necrotic and/or apoptotic cell death. To verify this
hypothesis, we assessed whether caspase 3/7, two enzymes in-
volved in the eﬀector phase of apoptosis, were a target of
CBs. Of note in our study, only the CB1 antagonist AM251 in-
Table 2
Combination index (CI) and dose reduction index (DRI) values for 5-FU plus AM251 combination schedule after 72 h
Concentrations (lM) Growth inhibition (%) CI values DRI values
AM251 5-FU AM251 5-FU
1 0.5 18.3 ± 1.8 0.53 ± 0.04* 2.98 ± 0.25 5.95 ± 0.38
1 1 25.7 ± 1.8 0.52 ± 0.03* 4.06 ± 0.27 3.75 ± 0.19
1 2.5 46.9 ± 1.2 0.54 ± 0.02* 7.88 ± 0.27 2.46 ± 0.06
1 5 58.2 ± 1.8 0.74 ± 0.03* 10.9 ± 0.58 2.46 ± 0.57
1 10 79.3 ± 1.5 0.80 ± 0.04 22.7 ± 1.59 1.35 ± 0.07
1 25 87.4 ± 0.9 1.41 ± 0.06 34.4 ± 1.79 0.73 ± 0.03
10 0.5 36.2 ± 1.5 1.86 ± 0.08* 0.56 ± 0.03 9.77 ± 0.33
50 0.5 84.5 ± 0.66 1.79 ± 0.06* 0.57 ± 0.02 32.0 ± 0.88
CI: combination index; DRI: dose reduction index. Data are expressed as means ± S.E. (n = 3). A CI value signiﬁcantly less than 1 indicates synergy,
a CI not signiﬁcantly diﬀerent from 1 indicates addition, and a CI signiﬁcantly higher than 1 indicates antagonism.
*P < 0.05.
1738 S. Fogli et al. / FEBS Letters 580 (2006) 1733–1739duced a signiﬁcant time-response eﬀect on caspase 3/7, at a
concentration that approximates its IC50 value. Accordingly,
internucleosomal degradation of DNA by AM251 was also
demonstrated suggesting that apoptosis may be a major con-
tributor to its anticancer action. Furthermore, our results dem-
onstrate that caspase 3/7 inhibition partially reverses the
toxicity of AM251; thus it is conceivable that apoptotic cell
death may be mediated, at least in part, via a caspase-depen-
dent mechanism.
These results seem to be relevant considering that develop-
ment of resistant mechanisms for apoptosis confers high sur-
vival ability and low drug sensitivity to pancreatic tumor
cells [12].
The diﬀerent apoptotic response of the CBs tested in the
current work may be caused by diﬀerences in their chemical
structures. Indeed, AM251 is a diarylpyrazole derivative
homologue to the cyclooxygenase-2 (COX-2) inhibitor cele-
coxib (Fig. 5), which, in turn, promotes apoptosis via activa-
tion of caspases 3/7 in the human breast cancer cell line
MDA-MB-231 [13]. MIA PaCa-2 is a COX-2-negative cell line
[14]; thus, COX-2 inhibition could not account for AM251
cytotoxicity. However, COX-2-inhibitory function is not re-
quired for celecoxib-mediated apoptosis which seems to be as-Fig. 5. Structural comparison between AM251 and the selective COX-
2 inhibitor, celecoxib.cribed to the delayed progression of cells through the G(2)/M
phase [15].
The mechanism underlying the cytotoxic action promoted
by JWH-015 and ACEA remains to be clariﬁed. However,
apart from necrosis, there are several pieces of evidence indi-
cating that cell death can occur in complete absence and inde-
pendent of caspase activation after cytotoxic drugs
administration, for example by autophagy, paraptosis, mitotic
catastrophe, and the descriptive model of apoptosis-like and
necrosis-like programmed cell death [16]. Some of these mech-
anisms may be taken into account to interpret the cytotoxic
eﬀect of JWH-015 and ACEA on MIA PaCa-2 cells.
To obtain further insights into molecular mechanism of ac-
tion of AM251, we examined the gene expression proﬁle of
MIA PaCa-2 cells after AM251 treatment by microarray anal-
ysis. Our data demonstrated that AM251 could aﬀect critical
steps of cell proliferation including JAK/STAT andMAPK sig-
naling network as well as cell cycle-related pathways. Despite of
the exploratory nature of microarray experiments did not allow
weighing the impact of the transcriptional changes in mediating
drug response, such a result appears to be in line with the ability
of celecoxib to induce apoptosis by modulating several ele-
ments controlling cell cycle check points [15,17].
Finally, we demonstrate that AM251 synergistically en-
hances the anticancer activity of 5-FU, one of the most com-
monly used drugs in the treatment of pancreatic carcinoma
[18]. Considering the celecoxib-AM251 molecular similarity,
these ﬁndings support clinical evidences demonstrating the eﬃ-
cacy of the celecoxib/5-FU combination schedule in patients
with advanced pancreatic cancer [19].
In conclusion, our data indicate that CB system does not
play a relevant role in MIA PaCa-2 cell proliferation and point
out AM251 as a prototypical compound for the development
of promising diarylpyrazole derivatives useful in ﬁghting pan-
creatic cancer.
Acknowledgements: We thank Drs. Massimiliano Salerno and Erika
Melissari for their support to microarray data analysis.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febs-
let.2006.02.024.
S. Fogli et al. / FEBS Letters 580 (2006) 1733–1739 1739References
[1] Hall, W., Christie, M. and Currow, D. (2005) Cannabinoids and
cancer: causation, remediation, and palliation. Lancet Oncol. 6,
35–42.
[2] Guzman, M., Sanchez, C. and Galve-Roperh, I. (2001) Control of
the cell survival/death decision by cannabinoids. J. Mol. Med. 78,
613–625.
[3] Sarfaraz, S., Afaq, F., Adhami, V.M. and Mukhtar, H. (2005)
Cannabinoid receptor as a novel target for the treatment of
prostate cancer. Cancer Res. 65, 1635–1641.
[4] Vaccani, A., Massi, P., Colombo, A., Rubino, T. and Parolaro,
D. (2005) Cannabidiol inhibits human glioma cell migration
through a cannabinoid receptor-independent mechanism. Br. J.
Pharmacol. 144, 1032–1036.
[5] Powles, T., te Poele, R., Shamash, J., Chaplin, T., Propper, D.,
Joel, S., Oliver, T. and Liu, W.M. (2005) Cannabis-induced
cytotoxicity in leukemic cell lines: the role of the cannabinoid
receptors and the MAPK pathway. Blood 105, 1214–1221.
[6] Ruiz, L., Miguel, A. and Diaz-Laviada, I. (1999) Delta9-tetrahy-
drocannabinol induces apoptosis in human prostate PC-3 cells via
a receptor-independent mechanism. FEBS Lett. 458, 400–404.
[7] Blazquez, C., Casanova, M.L., Planas, A., Del Pulgar, T.G.,
Villanueva, C., Fernandez-Acenero, M.J., Aragones, J., Huﬀman,
J.W., Jorcano, J.L. and Guzman, M. (2003) Inhibition of tumor
angiogenesis by cannabinoids. FASEB J. 17, 529–531.
[8] Casanova, M.L., Blazquez, C., Martinez-Palacio, J., Villanueva,
C., Fernandez-Acenero, M.J., Huﬀman, J.W., Jorcano, J.L. and
Guzman, M. (2003) Inhibition of skin tumor growth and
angiogenesis in vivo by activation of cannabinoid receptors. J.
Clin. Invest. 111, 43–50.
[9] Hart, S., Fischer, O.M. and Ullrich, A. (2004) Cannabinoids
induce cancer cell proliferation via tumor necrosis factor alpha-
converting enzyme (TACE/ADAM17)-mediated transactivation
of the epidermal growth factor receptor. Cancer Res. 64, 1943–
1950.[10] McKallip, R.J., Lombard, C., Fisher, M., Martin, B.R., Ryu, S.,
Grant, S., Nagarkatti, P.S. and Nagarkatti, M. (2002) Targeting
CB2 cannabinoid receptors as a novel therapy to treat malignant
lymphoblastic disease. Blood 100, 627–634.
[11] Chou, T.C., Tan, Q.H. and Sirotnak, F.M. (1993) Quantitation of
the synergistic interaction of edatrexate and cisplatin in vitro.
Cancer Chemother. Pharmacol. 31, 259–264.
[12] Yang, L., Cao, Z., Yan, H. and Wood, W.C. (2003) Coexistence
of high levels of apoptotic signaling and inhibitor of apoptosis
proteins in human tumor cells: implication for cancer speciﬁc
therapy. Cancer Res. 63, 6815–6824.
[13] Basu, G.D., Pathangey, L.B., Tinder, T.L., Gendler, S.J. and
Mukherjee, P. (2005) Mechanisms underlying the growth inhib-
itory eﬀects of the cyclo-oxygenase-2 inhibitor celecoxib in human
breast cancer cells. Breast Cancer Res. 7, R422–R435.
[14] Yip-Schneider, M.T., Barnard, D.S., Billings, S.D., Cheng, L.,
Heilman, D.K., Lin, A., Marshall, S.J., Crowell, P.L., Marshall,
M.S. and Sweeney, C.J. (2000) Cyclooxygenase-2 expression in
human pancreatic adenocarcinomas. Carcinogenesis 21, 139–146.
[15] Ding, H., Han, C., Zhu, J., Chen, C.S. and D’Ambrosio, S.M.
(2005) Celecoxib derivatives induce apoptosis via the disruption
of mitochondrial membrane potential and activation of caspase 9.
Int. J. Cancer 113, 803–810.
[16] Bro¨ker, L., Kruyt, F.A.E. and Giaccone, G. (2005) Cell death
independent of caspases: a review.Clin. CancerRes. 11, 3155–3162.
[17] Subhashini, J., Mahipal, S.V. and Reddanna, P. (2005) Anti-
proliferative and apoptotic eﬀects of celecoxib on human chronic
myeloid leukemia in vitro. Cancer Lett. 224, 31–43.
[18] Willett, C.G., Czito, B.G., Bendell, J.C. and Ryan, D.P. (2005)
Locally advanced pancreatic cancer. J. Clin. Oncol. 23, 4538–
4544.
[19] Milella, M., Gelibter, A., Di Cosimo, S., Bria, E., Ruggeri, E.M.,
Carlini, P., Malaguti, P., Pellicciotta, M., Terzoli, E. and
Cognetti, F. (2004) Pilot study of celecoxib and infusional 5-
ﬂuorouracil as second-line treatment for advanced pancreatic
carcinoma. Cancer 101, 133–138.
